Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.57 +0.48 (+3.71%)
Streaming Delayed Price Updated: 2:01 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
News headline image
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming ↗
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. 
Via InvestorPlace
News headline image
Technical Analysis : Pinduoduo (PINS) & Intellia Therapeutics (NTLA) ↗
Here's a technical analysis of two stocks: Pinduoduo (PDD) & Intellia Therapeutics. 
Via Talk Markets
News headline image
CareDx & Intellia Therapeutics Elliott Wave Analysis ↗
At this point the flat correction into wave (4) could be completed, if not we are just missing one last leg down. 
Via Talk Markets
News headline image
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today ↗
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. 
Via InvestorPlace
News headline image
US Stocks: AME, AVAV, NIO, NTLA, PDD & SNAP Technical Analysis ↗
Technical stocks analysis: Ametek, AeroVironment, Nio Inc, Intellia Therapeutics, Pinduoduo, and Snap. 
Via Talk Markets
Where Intellia Therapeutics Stands With Analysts ↗
Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst rati... 
Via Benzinga
Why Intellia Therapeutics' Stock Is Trading Higher Today ↗
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading si... 
Via Benzinga
Why Intellia Therapeutics Shares Are Trading Higher Today ↗
... 
Via Benzinga
Unusual Options Activity Insight: Intellia Therapeutics ↗
On Friday, shares of Intellia Therapeutics (NASDAQ:NTLA) ... 
Via Benzinga
News headline image
Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript ↗
NTLA earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
10 Biggest Price Target Changes For Friday ↗
Piper Sandler boosted the price target for Moderna, Inc. (NASDAQ: MRNA) from $246 to $445. Moderna shares fell 1.6% to $409.55 in pre-market trading. Needham cut the price... 
Via Benzinga
News headline image
Why Shares of Intellia Therapeutics Are Jumping Today ↗
More progress in the pipeline has investors bullish on the company's shares. 
Via The Motley Fool
News headline image
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today ↗
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
Via InvestorPlace
News headline image
3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio ↗
The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap. 
Via The Motley Fool
News headline image
99 Biggest Movers From Yesterday ↗
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
News headline image
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week ↗
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains. 
Via The Motley Fool
News headline image
After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding ↗
It's a good time to be a gene-editing company. 
Via The Motley Fool
News headline image
Russell 2000 Traders Place Bearish Bets Via IWM ETF ↗
The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM... 
Via Benzinga
News headline image
WHO Issues Framework For Governance For Gene Editing Technologies ↗
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or... 
Via Benzinga
News headline image
A Comprehensive Guide To Genomic ETFs ↗
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
News headline image
Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results ↗
There are still some key unanswered questions for the biotech's promising gene-editing therapy. 
Via The Motley Fool
News headline image
US Stocks Technical Analysis: AVAV, ESLT, ICE, HDFC, NTLA & NVDA ↗
Elliott Wave Technical Analysis for AeroVironment, Elbit Systems, Intercontinental Exchange, HDFC Bank Limited, Intellia Therapeutics, and Nvidia. 
Via Talk Markets
News headline image
Is It Too Late to Buy Intellia Therapeutics? ↗
After skyrocketing 68% last week, will this stock keep running higher? 
Via The Motley Fool
News headline image
Here's Why Regeneron Gained 11% Last Month ↗
The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands. 
Via The Motley Fool
News headline image
2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't ↗
After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed. 
Via The Motley Fool
News headline image
Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus ↗
The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped. 
Via Investor's Business Daily
Topics Initial Public Offering Stocks
News headline image
Here's What Drove Gene Editing Stocks Higher This Week ↗
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers. 
Via The Motley Fool
News headline image
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.